Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
New London office will accommodate rapidly growing team and facilitate client collaboration
LONDON, April 28, 2014 /PRNewswire/ -- Evidera, an industry leading pharmaceutical research and consulting business, today announced the opening of a new London office, consolidating two previous sites in the city and creating room for continued growth. Evidera provides health economics, outcomes research, market access and epidemiology services to the world's top biopharmaceutical companies.
The new European head office will strengthen the company's global footprint, joining other major offices in Bethesda, Maryland; Lexington, Massachusetts and San Francisco, California. Evidera also has offices in Seattle, Montreal and Budapest. The new office will house approximately 100 of the company's 350 experts who help the firm's clients optimise market access and maximise commercial success for their products.
The new space, customised to facilitate collaboration between the company's teams, is located in the thriving west London office hub of Hammersmith, alongside major corporations such as L'Oreal and Coca-Cola. Well placed for international travel and convenient access within London, the office provides a modern, comfortable and effective space for staff and clients to work together collaboratively. The bright, open design will address the needs of the business as it grows and facilitate expansion into new and adjacent services.
"This is about more than great new office space for our staff to work in and clients to visit," said Evidera President and CEO, Jon Williams. "It's a key element of our strategy for European growth, and an important step forward as we develop new ways of collaborating with our clients to provide integrated solutions to address their complex problems. It strengthens our presence in Europe and provides a fantastic platform to build our business further and attract new talent."
Look for more information at www.evidera.com.
Evidera, a wholly owned subsidiary of Symphony Technology Group, is one of the preeminent commercial entities analysing effectiveness, establishing evidence, and substantiating the value of treatments within the global health industry through its market leading portfolio of health economics, outcomes research, market access, data analytics and epidemiology services. Evidera partners with life sciences organizations worldwide to optimize the market access and commercial success of their products by leveraging unparalleled knowledge of the global payer and regulator landscape and by developing, capturing and communicating the clinical and economic evidence that our clients require to successfully market their products. Our research and consulting services are driven by world-class science and thought leadership and leverage a unique combination of capabilities. For more information, please visit www.evidera.com.
About Symphony Technology Group
Symphony Technology Group (STG) is a strategic private equity firm with the mission of investing in and building great technology and services companies. In addition to capital, STG provides transformation expertise to enable its companies to deliver maximum value to their clients, to drive growth through innovation, to retain and attract the best talent and to achieve best in class business performance. STG's current portfolio consists of 14 global companies. For more information, please visit www.symphonytg.com.
For media information, please contact:
Susan Potter Couch
+1 301 664 7286
©2012 PR Newswire. All Rights Reserved.